Clinical trials: Bone Marrow
Fanconi Anemia
Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia
Fanconi anemia (FA) is a disease that affects an individual's bone marrow. It is caused by a defective gene in the bone marrow cells that produce various types of blood cells.
- Trial name
- NCT00272857
- Testing
- Retrovirus Construct
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston Children's Hospital
Myelofibrosis
Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels
This study was an observational study, and about 40 patients with intermediate and high risk myelofibrosis who had participated in any previous clinical study of Gecacitinib hydrochloride and were still receiving Gecacitinib…
- Trial name
- NCT07342712
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Chronic Myelogenous Leukemia
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
The goal of this clinical research study is to find out if IL-11 (NeumegaTM) may increase the platelet count in patients with Chronic myeloid leukemia (CML) who develop low platelet counts while receiving therapy with imatinib…
- Conditions
- Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT00493181
- Testing
- Interleukin-11 (IL-11 or Neumega)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Epstein-Barr Virus Infections
Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts
Patients have a type of blood cell cancer or other blood problem that is very hard to cure with standard treatments and s/he will receive a bone marrow transplant.
- Trial name
- ETNA (NCT00058812)
- Testing
- EBV specific T cells
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Baylor College of Medicine
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.
- Conditions
- Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT02556931
- Testing
- Fludarabine, Cyclophosphamide, Total body irradiation
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chronic Lymphocytic Leukemia, Graft vs Host Disease
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
Allogeneic peripheral blood stem cell transplantation (PBSCT) is primarily limited by graft-versus-host disease (GVHD). In murine models, we have demonstrated that donor CD4+ T cells of Th1 cytokine phenotype (defined by their…
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hodgkin's Disease, Multiple Myeloma
- Trial name
- NCT00001830
- Testing
- Th2 cells in allo HSCTT, Th2 Cells
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Granulomatous Disease
Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease
This study will investigate the safety and effectiveness of a modified stem cell transplant procedure for treating chronic granulomatous disease (CGD) in patients with active infection.
- Trial name
- NCT00001765
- Testing
- Nexell Isolex with T-cell Depletion, Baxter isolex 300i
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leukemia, Myeloid, Chronic
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
The goal of this clinical research study is to learn if giving PEG-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec (imatinib mesylate) is more effective in treating…
- Trial name
- NCT00050531
- Testing
- Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF)
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center
Viral Infections
Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010
Background: Some blood and immune disorders can be helped with HSCT. This is allogeneic hematopoietic stem cell transplantation. The person who gets the stem cells has their immune system suppressed.
- Trial name
- NCT03111745
- Where
- United States
- Volunteers
- 730 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Bone Marrow Tumor Cell Infiltration
Disseminated Tumour Cells (DTC) in Left Sided Colorectal Cancer (LSCC).
Two metaanalyses of studies on the prognostic significance of circulating cancer cells in colorectal cancer indicated, that the presence of circulating tumour cells (CTC) in the peripheral blood is the negative prognostic factor.
- Trial name
- NCT03640572
- Testing
- Bone marrow analysis to identify disseminated tumour cells
- Where
- Poland
- Volunteers
- 91 people
- Sponsor
- Jagiellonian University
Chronic Myeloproliferative Disorders, Leukemia
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- LCCC0510 (NCT00448357)
- Testing
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Type 1 Diabetes Mellitus
Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen
The goal of islet cell transplantation in Type 1 diabetics is to provide those affected with constant normal blood glucose levels, thereby reducing or eliminating altogether the need for injected insulin.
- Trial name
- NCT00021801
- Testing
- Islet Cell Transplantation
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow doctors to give higher doses of…
- Trial name
- NCT00003436
- Testing
- amsacrine, asparaginase, cytarabine
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Medical Research Council
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
The Drugs Controller General of India (DCGI) has granted approval for Asciminib film-coated 40 mg tablets on 20 Oct 2023 with the condition to perform a Phase IV clinical study in Indian patients with Philadelphia…
- Trial name
- ASC4INDIA (NCT06427811)
- Testing
- Asciminib
- Where
- 10 sites in India
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML)
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation.
- Trial name
- ASC4TARGET (NCT06514534)
- Testing
- ABL001/Asciminib
- Where
- 6 sites in France
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, End Stage Renal Disease
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
The primary objective is to cure multiple myeloma with less toxic allogeneic bone marrow transplantation while inducing renal allograft tolerance through mixed chimerism in patients with end stage renal failure and multiple…
- Trial name
- NCT00854139
- Testing
- Cyclophosphamide, anti-thymocyte globulin, Kidney transplant, Thymic irradiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Severe Aplastic Anemia, Telomere Biology Disorders
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes
Background: Bone marrow failure diseases are rare. Much is known about the diseases at the time of diagnosis, but long-term data about the effects of the diseases and treatments are lacking.
- Conditions
- Severe Aplastic Anemia, Telomere Biology Disorders, Inherited Bone Marrow Failure Syndromes
- Trial name
- NCT05012111
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow…
- Conditions
- Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
- Trial name
- NCT01928537
- Testing
- rigosertib sodium
- Where
- 35 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Traws Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.